Edgewise Therapeutics' EDG-7500 Shows Significant Progress in Heart Disease Treatment

Boulder, Wednesday, 2 April 2025.
Edgewise Therapeutics reports a 71% reduction in heart obstruction with EDG-7500, promising improved treatment for hypertrophic cardiomyopathy and boosting potential investment interest.